The region overlapped with the promoter region of FOXE1, and the variability of genotypes was associated with differential activity levels of an enhancer, further leading to variations in FOXE1 expression that resulted in altered risk of thyroid cancer. Here, FOXE1 is linked to thyroid gland carcinoma.